PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting LYT-200 is being advanced in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback